The GLP-1 receptor agonist market size, valued at USD 78 billion in 2025, is projected to reach USD 101.4 billion in 2026 and USD 180 billion by 2035, representing a CAGR of 6.6% during the forecast period 2026 to 2035. In recent years, there has been a notable shift in consumer lifestyles driven by the growing influence of social media, celebrity endorsements and direct-to-consumer advertising. This has led to a surge in the demand for weight loss and type 2 diabetes treatment solutions, which...

The next generation drug conjugates market, valued at USD 8.0 billion in 2025, is projected to reach USD 11.2 billion in 2026 and USD 26.2 billion by 2035, representing a CAGR of 9.9% during the forecast period 2026 to 2035. In terms of type of drug conjugate, ligand mediated RNAi conjugates hold the highest share (around 55%) of the current market. With respect to type of targeting ligand, next generation drug conjugates with amino sugar dominate (more than 60%) the current market.

The global anti-aging drugs for dogs market, valued at USD 0.09 billion in 2026, is projected to reach USD 6.16 billion by 2040, with a 36% CAGR during the forecast period 2026 to 2040. Over the years, the pet dog population has increased at a substantial rate. According to the American Veterinary Medical Association, the dog population has steadily increased from 52.9 million in 1996 to 89.7 million in 2024. Also, the number of pet-owning households has increased from 31.3 million in 1996 to 59...

The global anti-obesity drugs market, valued at USD 28.2 billion in 2025, is projected to reach USD 45.1 billion in 2026 and USD 106.5 billion by 2035, representing a CAGR of 10.0% during the forecast period 2026 to 2035. In terms of route of administration, parenteral route captures the highest share of the current market.Based on the distribution channel, retail and online pharmacies are likely to capture the highest share of the current market. In terms of key geographical regions, North Amer...

The global teleradiology services market, valued at USD 9.2 billion in 2025, is projected to reach USD 10.1 billion in 2026 and USD 23.3 billion by 2035, representing a CAGR of 9.7% during the forecast period 2026 to 2035. In terms of imaging modality, CT scan accounted for 35% of market revenues in 2026.With respect to end user, hospitals (51%) dominate the current market.

The global female sexual dysfunction market reached USD 0.61 billion in 2026 and is projected to reach USD 2.87 billion by 2040, growing at a CAGR of 11.7% over the forecast period 2026 to 2040, driven by broader treatment eligibility and delivery innovation. Treatment demand is shifting from menopause-centered symptom management toward broader desire, arousal, pain, and orgasm-focused care. Estrogen therapy still leads drug demand with 41.0% share in 2026, while oral therapies hold 58.0% across...

The global non-small cell lung cancer market size is estimated to grow from USD 23.8 billion in 2025 to USD 26.4 billion in 2026 and USD 56.0 billion by 2035, representing a CAGR of 8.7% during the forecast period. It is worth highlighting that among all the forms of non-small cell lung cancer, squamous cell carcinoma is one of the most common types and it may develop due to prolonged use of tobacco. In fact, the World Health Organization report shows that smoking is the main cause of lung cance...

The small molecule API manufacturing market, valued at USD 197 billion in 2025, is projected to reach USD 204 billion in 2026 and USD 266 billion by 2035, representing a CAGR of 3.0% during the forecast period 2026 to 2035. In terms of type of manufacturers, the in-house manufacturers are likely to secure ~65% of the overall revenue share in 2026, due to the growing preference towards large, vertically integrated pharmaceutical companies. In March 2026, Cambrex announced the initial completion o...

The global GLP-1 manufacturing market is expected to rise from USD 14.6 billion in 2026 to reach USD 88.5 billion by 2040, growing at a CAGR of 13.7% over the forecast period 2026 to 2040, driven by chronic obesity and cardiometabolic demand. Based on manufacturing stage, drug substance / peptide API synthesis captures 35.0% market share in 2026, whereas device assembly and secondary packaging registers a 16.5% CAGR through 2040, driven by pen and combination-product scale-up. Based on manufactu...

The global cell encapsulation market, valued at USD 5.0 billion in 2025, is projected to reach USD 5.7 billion in 2026 and USD 15.8 billion by 2035, representing a CAGR of 12.0% during the forecast period 2026 to 2035. In April 2026, Atelerix signed a strategic partnership agreement with JH Health to expand the distribution and use of its proprietary non-cryogenic hydrogel encapsulation and cell preservation technology in the Middle East. In March 2026, researchers at MIT published findings on a...

The global male contraceptives market is expected to rise from USD 16.5 billion in 2026 to reach USD 38.6 billion by 2040, growing at a CAGR of 6.3% over the forecast period 2026 to 2040, driven by reversible product innovation. Based on duration of action, single-use coital methods capture 72.0% market share in 2026, whereas on-demand pharmacological methods register a 38.3% CAGR through 2040, reducing adherence burdens. Based on distribution channel, drugstores and retail pharmacies capture 33...

The global viral vector and plasmid DNA manufacturing market, valued at USD 843 million in 2025, is projected to reach USD 937 million in 2026 and USD 2,161 million by 2035, with a CAGR of 9.73% during the forecast period 2026 to 2035. Presently, over 300 industry and non-industry players across the globe are actively involved so as to support the expanding pipeline of cell therapies, gene therapies, and vector-based vaccines, as per viral vectors and plasmid DNA manufacturing market report. In...

The global T-Cell Engagers Market reached USD 8.6 billion in 2026 and is projected to reach USD 62.5 billion by 2040, growing at a CAGR of 15.2% over the forecast period 2026 to 2040, driven by expanding hematologic approvals and early solid-tumor validation. Hematology-led adoption has shifted the T-cell engagers market from niche leukemia use toward broader CD3-directed bispecific commercialization. CD20, BCMA, and GPRC5D products now anchor demand across lymphoma and myeloma. DLL3 validation...

The global peptide synthesis market, valued at USD 3.8 billion in 2025, is projected to reach USD 4.2 billion in 2026 and USD 6.0 billion by 2035, at a CAGR of 4.1% during the forecast period 2026 to 2035. The generics segment secures 88% of the overall revenue share primarily due to the patent expirations of first-generation peptide drugs and high costs associated with branded therapies. In terms of type of peptide synthesis method, chemical synthesis method currently holds 85% of the overall m...

The back of the eye disorders market, valued at USD 17.06 billion in 2025, is projected to reach USD 18.28 billion in 2026 and USD 41.56 billion by 2035, representing a CAGR of 9.6% during the forecast period 2026 to 2035. Kindly note that implants and devices related to the back of the eye disorders market have been excluded from the scope of this report. In terms of geographical regions, North America captures around 60% of the market value in the year 2026, due to strong public and private i...

The global biopharmaceutical excipients manufacturing market, valued at USD 3.3 billion in 2025, is projected to reach USD 3.6 billion in 2026 and USD 6.3 billion by 2035, representing a CAGR of 6.4% during the forecast period 2026 to 2035. Emerging innovations, particularly in lipid-based excipients for mRNA vaccines and therapeutics, are further expanding the excipient landscape. Coupled with the rising trend in outsourcing and growing regulatory support for novel excipients, the use of biopha...

The global atrial fibrillation market, valued at USD 20.9 billion in 2025, is projected to reach USD 21.4 billion in 2026 and USD 38.7 billion by 2035, representing a CAGR of 6.8% during the forecast period 2026 to 2035. The market includes both treatment drugs and devices for atrial fibrillation (AFib). In 2024, the CDC identified AFib as the most common heart arrhythmia treated in the US. The number of Americans affected is projected to reach 12.1 million by 2030, with AFib contributing to rou...

The large molecule bioanalytical testing services market, valued at USD 2.89 billion in 2025, is projected to reach USD 3.11 billion in 2026 and USD 5.88 billion by 2035, representing a CAGR of 7.3% during the forecast period 2026 to 2035. In terms of end-user, the pharmaceutical and biotechnology companies account for around 50% of the overall revenue share. In terms of geographical regions, North America holds close to 50% of the market share due to its strong public and private investments, s...

The global bioanalytical testing services market, valued at USD 4.94 billion in 2025, is projected to reach USD 5.38 billion in 2026 and USD 10.90 billion by 2035, representing a CAGR of 8.2% during the forecast period. Based on the type of molecule, the global market is segmented into small molecules, large molecules and others. According to our projections, small molecules segment currently holds 56% of the bioanalytical testing services market share. As per our global bioanalytical testing se...

The global microbial fermentation CMO market, valued at USD 3.8 billion in 2025, is projected to reach USD 4.3 billion in 2026 and USD 9.6 billion by 2035, with a CAGR of 9.4% during the forecast period 2026 to 2035. Presently, there are a number of traditional and innovative microbial expression systems / platforms, based on bacteria, fungi and yeast, which are used for manufacturing a variety of conventional and complex biologics. Contract manufacturers engaged in this domain have forged sever...